The Endpoints 11 : Here are some of the most promising startups in biotech. And Covid-19 isn’t going to stop them

Bill Haney, an entrepreneur and filmmaker who has a finger in a multitude of pots, got this biotech started with a mere $8 million in seed cash. Since then, he’s brought in hundreds of millions more from marquee partners like Merck who have been convinced that the startup has the key to drugging RNA — one of the hottest plays in the discovery field.

Scroll to Top